ANL · Adlai Nortye Group Ltd.

Adlai Nortye Ltd Is A Clinical-Stage Company At The Forefront Of Discovering And Developing Cancer Therapies. The Company Is Building A Robust Pipeline Of Drug Candidates Focused On Two Key Areas Where It Believes It Can Make A Difference Ras-Targeting Therapies: Its Is Tackling Ras-Driven Cancers With An9025, An Oral Pan-Ras(On) Inhibitor, And An4035, A Ceacam5-Targeting Adc Delivering A Potent Pan-Ras(On) Inhibitor Directly To Tumors; Next-Generation Cancer Immunotherapies: Its Candidates, An8025 (A Tri-Functional Fusion Protein Of Alphapd-L1 X Cd86 Variant X Lag3 Variant), A T-Cell And Antigen-Presenting Cell Modulator, And An4005 (A First-In-Class Oral Small-Molecule Pd-L1 Inhibitor), Are Designed To Activate Cancer Immunity In Novel Ways.